Delivery Order 75N95022D00023-75N95024F00002
- This is a $5,724,344 federal contract award issued by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is a delivery order under the larger "Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders" Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $149.2...
- This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract is for the provision of expertise in ethnographic research related to the enhancement of study drug adherence and uptake in human immunodeficiency virus (HIV) prevention trials. The contract has a ceiling value of...
- This is a cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned for-profit manufacturer of goods. The $8,997,298.00 contract supports the production of ALVAC-HIV drug product and diluent as part of NIAID's Preclinical Development Support program. ABL, a contract research and manufacturing...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The contract, with a ceiling value of $186,316.03, is for the manufacture and characterization of vaccines and other biologics. ABL, a foreign-owned, for-profit organization that specializes in biopharmaceutical research and development, is a leading contract research and manufacturing...
- This is a $1,207,640.00 cost-plus-fixed-fee delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for process and analytical development of BITOX. The contract is a task order under NCATS' larger CRO Support for NCATS Drug Substance Development and Manufacture indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The...
- This federal contract award is for the PRODUCTION OF ADJUVANTS by Advanced Bioscience Laboratories, Inc. (ABL), a for-profit organization and manufacturer of goods. The contract, valued at $1,458,936.50, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, with an ultimate completion...
- The National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services, awarded a $16,000 purchase order to Cellx, Inc., a small business, on September 29, 2025, for pharmaceutics formulation, chemistry manufacturing and controls (CMC) consulting services supporting drug discovery and development programs. The contract, which runs through September 28, 2028, provides specialized subject matter expert consultation for small molecules and biologics development, with...
- The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $382,010.00 Firm Fixed Price Delivery Order contract to Vitae Enim Vitae Scientific, Inc. (VEV Scientific) on September 27, 2024. The contract is for dosage form reprocessing and stability studies of the FX-5A injection drug product under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Chemistry, Manufacturing and Controls (CMC) and related services to support drug product development. The contract...
- This is a task order awarded under the Preclinical Services for Biopharmaceutical Product Development indefinite-delivery/indefinite-quantity (IDIQ) contract by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases. The $110,115.92 task order was awarded to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit organization that specializes in manufacturing and testing biologics such as gene therapies, vaccines, and immunotherapies....
- This federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) is for the "SIMIAN VACCINE EVALUATION UNITS" program, which is a delivery order under a larger Indefinite Delivery Vehicle (IDV) contract with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract, valued at $2,833,961.28, is for cGMP manufacturing, testing, and other services to support the development of vaccines and other...
- 75N95022D00023Indefinite Delivery Contract
- 75N95022D00023-75N95024F00002Delivery Order
The U.S. National Institute on Drug Abuse (NIDA) awarded a $13,049,822.20 delivery order contract to Advanced Bioscience Laboratories, Inc. (ABL) for the current good manufacturing practice (cGMP) manufacture of VHCA8* for the treatment of pain. This award is part of a larger $149.2 million indefinite delivery vehicle (IDV) with NIDA for Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders. The contract has an ultimate completion date of April 29, 2027 and does not have a set-aside designation. ABL is a large, for-profit biopharmaceutical contract research and manufacturing organization that has supported numerous federal contracts and grants, particularly from NIH institutes such as NIAID, NCI, and NINDS, for the development of vaccines, therapeutics, and diagnostics across various disease areas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00004 | Exercise an Option | $3.1m | 5/29/25 | |
| P00003 | Exercise an Option | $680.0k | 11/14/24 | |
| P00002 | Change Order | $65.0k | 9/23/24 | |
| P00001 | Exercise an Option | $3.6m | 4/30/24 | |
| Not listed | Not listed | $2.0m | 3/11/24 |